NeOnc’s Powerful Brain Cancer Pipeline Advances
NeOnc Technologies has an FDA End-of-Phase 1 Type B meeting scheduled for November 17, 2026, to discuss NEO212's proposed Phase 2 design, endpoints, dose selection and potential accelerated-approval strategy for aggressive CNS cancers. NEO212 completed Phase 1 with a recommended Phase 2 dose of 610 mg, supported by individual-patient signals (including ~60% tumor reduction in a recurrent glioblastoma patient) that are not controlled efficacy evidence. Lead program NEO100 previously beat its prespecified benchmark with 48.9% six-month progression-free survival versus 20% in recurrent IDH1-mutant glioma.
Key figures
- Drug Name
- NEO212
- Phase Of Trial
- End-of-Phase 1
- Offering price
- $4.20
- Fda meeting date
- November 17, 2026
- Insider purchases
- approximately $629,000
- Offering proceeds
- $15 million
- Neo100 6mo pfs pct
- 48.9%
- Analyst price target
- $20
- Preferred redemption
- $6 million
- Max tolerated dose mg
- 810
- Neo100 6mo pfs pvalue
- 0.0047
- Patients alive 6mo pct
- 86.7%
- Neo100 median os months
- 26.09
- Recommended phase2 dose mg
- 610
- Neo100 6mo pfs benchmark pct
- 20%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.